Global Medical REIT (GMRE)
(Delayed Data from NYSE)
$9.22 USD
+0.12 (1.32%)
Updated Nov 5, 2024 04:00 PM ET
Pre-Market: $9.29 +0.07 (0.76%) 9:18 AM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Income Statements
Fiscal Year end for Global Medical REIT Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 141 | 137 | 116 | 94 | 71 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 141 | 137 | 116 | 94 | 71 |
Selling & Adminstrative & Depr. & Amort Expenses | 103 | 99 | 79 | 78 | 43 |
Income After Depreciation & Amortization | 38 | 38 | 37 | 16 | 27 |
Non-Operating Income | 15 | 7 | 1 | 0 | 0 |
Interest Expense | 31 | 25 | 20 | 19 | 17 |
Pretax Income | 22 | 20 | 18 | -3 | 10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1 | 1 | 1 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 22 | 20 | 18 | -3 | 10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 21 | 19 | 18 | -2 | 9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 99 | 98 | 86 | 54 | 54 |
Depreciation & Amortization (Cash Flow) | 61 | 60 | 49 | 38 | 27 |
Income After Depreciation & Amortization | 38 | 38 | 37 | 16 | 27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 65.55 | 65.46 | 60.64 | 46.26 | 33.87 |
Diluted EPS Before Non-Recurring Items | 0.23 | 0.20 | 0.19 | -0.17 | 0.10 |
Diluted Net EPS (GAAP) | 0.23 | 0.20 | 0.19 | -0.17 | 0.10 |
Fiscal Year end for Global Medical REIT Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 34.24 | 35.12 | 32.96 | 35.51 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 34.24 | 35.12 | 32.96 | 35.51 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 25.82 | 25.91 | 24.56 | 25.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.42 | 9.21 | 8.40 | 9.71 |
Non-Operating Income | NA | -3.38 | 0.00 | 0.00 | 2.29 |
Interest Expense | NA | 6.99 | 6.89 | 6.98 | 7.17 |
Pretax Income | NA | -1.95 | 2.31 | 0.55 | 4.83 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.26 | 0.07 | -0.07 | 0.24 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.95 | 2.31 | 0.55 | 4.83 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.69 | 2.25 | 0.62 | 4.59 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 65.59 | 65.57 | 65.57 | 65.57 |
Diluted EPS Before Non-Recurring Items | NA | -0.05 | 0.01 | -0.01 | 0.05 |
Diluted Net EPS (GAAP) | NA | -0.05 | 0.01 | -0.01 | 0.05 |